Brief: PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer
13/03/2025 13:47
March 13 (Reuters) - PDS Biotechnology Corp PDSB.O: PDS BIOTECH ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR COMBINATION OF VERSAMUNE® MUC1 AND PDS01ADC TO TREAT METASTATIC COLORECTAL CANCER Source text: ID:nGNX4FXJkf Further company coverage: PDSB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing